Med BioGene says lymphoma DNA test diagnoses subtypes

By Elaine Rigoli

Tampa, Fla., Aug. 3 - Med BioGene, Inc. announced the results of its preclinical studies involving its diagnostic lymphoma bioarray, in which 50 RNA samples derived from human lymphoma tissues suggested the test successfully differentiated between genes in both the diseased and healthy control samples.

Moreover, the company noted that the results revealed a high dissimilarity between six lymphoma subtypes (Diffuse Large B-Cell, Mantle Cell, Follicular, Hodgkin, Marginal Zone and Small Lymphocytic) and the healthy control samples, indicating that the bioarray is able to detect differential expression profiles.

Med BioGene is a biotechnology company based in Vancouver, B.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.